Haleh Saber

3.0k total citations · 1 hit paper
20 papers, 1.6k citations indexed

About

Haleh Saber is a scholar working on Oncology, Genetics and Immunology. According to data from OpenAlex, Haleh Saber has authored 20 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Genetics and 5 papers in Immunology. Recurrent topics in Haleh Saber's work include Chronic Lymphocytic Leukemia Research (5 papers), CAR-T cell therapy research (4 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Haleh Saber is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), CAR-T cell therapy research (4 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Haleh Saber collaborates with scholars based in United States, Egypt and United Kingdom. Haleh Saber's co-authors include John K. Leighton, Richard Pazdur, Ann T. Farrell, Robert Justice, Jeffrey C. Hansen, Borries Demeler, Rajeshwari Sridhara, Brian Booth, David E. Morse and Robert C. Kane and has published in prestigious journals such as Nature Reviews Drug Discovery, Clinical Cancer Research and Biophysical Journal.

In The Last Decade

Haleh Saber

20 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trends in the approval of cancer therapies by the FDA in the twenty-first century

2023 155 citations Emma Scott, Andrea Baines et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Haleh Saber United States	13	624	606	276	243	235	20	1.6k
John K. Leighton United States	18	670 1.1×	463 0.8×	424 1.5×	270 1.1×	220 0.9×	34	1.6k
Nida Iqbal India	8	537 0.9×	591 1.0×	117 0.4×	102 0.4×	294 1.3×	10	1.4k
Myrna Candelaria Mexico	25	1.4k 2.3×	563 0.9×	129 0.5×	128 0.5×	131 0.6×	88	2.5k
Maeva Dufies France	25	734 1.2×	388 0.6×	185 0.7×	133 0.5×	52 0.2×	46	1.5k
Rosemary L. Balleine Australia	23	649 1.0×	791 1.3×	101 0.4×	108 0.4×	118 0.5×	58	2.0k
R. Osieka Germany	28	1.1k 1.8×	693 1.1×	376 1.4×	233 1.0×	360 1.5×	89	2.4k
Edward M. Newman United States	26	1.1k 1.8×	1.2k 1.9×	156 0.6×	210 0.9×	96 0.4×	88	2.4k
Ron Yu United States	14	724 1.2×	949 1.6×	92 0.3×	136 0.6×	391 1.7×	32	1.7k
James F. Eliason United States	24	1.1k 1.8×	601 1.0×	536 1.9×	202 0.8×	165 0.7×	72	2.5k
Hie‐Won Hann United States	24	648 1.0×	223 0.4×	289 1.0×	190 0.8×	85 0.4×	70	2.1k

Countries citing papers authored by Haleh Saber

Since Specialization

Citations

This map shows the geographic impact of Haleh Saber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haleh Saber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haleh Saber more than expected).

Fields of papers citing papers by Haleh Saber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haleh Saber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haleh Saber. The network helps show where Haleh Saber may publish in the future.

Co-authorship network of co-authors of Haleh Saber

This figure shows the co-authorship network connecting the top 25 collaborators of Haleh Saber. A scholar is included among the top collaborators of Haleh Saber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haleh Saber. Haleh Saber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saber, Haleh, Matthew D. Thompson, & John K. Leighton. (2024). Pharmacokinetic models for first-in-human dose selection of immune-activating products in oncology. Regulatory Toxicology and Pharmacology. 149. 105616–105616. 3 indexed citations

Scott, Emma, Andrea Baines, Yutao Gong, et al.. (2023). Trends in the approval of cancer therapies by the FDA in the twenty-first century. Nature Reviews Drug Discovery. 22(8). 625–640. 155 indexed citations breakdown →

Saber, Haleh, et al.. (2020). IMPACTS OF ZINC OXIDE NANO-PARTICLES SUPPLEMENTATION IN BROILER DIETS ON GROWTH PERFORMANCE, SOME CARCASS CHARACTERISTICS AND IMMUNE ORGANS. Egyptian Journal of Nutrition and Feeds. 23(1). 113–122. 8 indexed citations

Manning, Michael L., et al.. (2019). An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology products. Regulatory Toxicology and Pharmacology. 110. 104511–104511. 5 indexed citations

Saber, Haleh, Natalie E. Simpson, Tiffany K. Ricks, & John K. Leighton. (2019). An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates. Regulatory Toxicology and Pharmacology. 107. 104429–104429. 61 indexed citations

Saber, Haleh, et al.. (2018). INTERACTION EFFECT OF DIETARY CRUDE PROTEIN AND ORGANIC ACIDS ON GROWTH PERFORMANCE, CARCASS CHARACTERISTICS AND IMMUNE ORGANS OF BROILER CHICKS. Egyptian Journal of Nutrition and Feeds. 21(1). 155–170. 2 indexed citations

Walker, Amanda J., Hyun Kim, Haleh Saber, et al.. (2017). Clinical Development of Cancer Drugs in Combination With External Beam Radiation Therapy: US Food and Drug Administration Perspective. International Journal of Radiation Oncology*Biology*Physics. 98(1). 5–7. 6 indexed citations

Saber, Haleh, et al.. (2017). An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection. Regulatory Toxicology and Pharmacology. 90. 144–152. 60 indexed citations

Saber, Haleh, Ramadevi Gudi, Michael L. Manning, Emily Wearne, & John K. Leighton. (2016). An FDA oncology analysis of immune activating products and first-in-human dose selection. Regulatory Toxicology and Pharmacology. 81. 448–456. 33 indexed citations

10.

Leighton, John K., Haleh Saber, Gregory H. Reaman, & Richard Pazdur. (2016). An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs. Regulatory Toxicology and Pharmacology. 79. 142–143. 6 indexed citations

11.

Deisseroth, Albert, Chia‐Wen Ko, Lei Nie, et al.. (2015). FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease. Clinical Cancer Research. 21(5). 950–954. 86 indexed citations

12.

Saber, Haleh & John K. Leighton. (2015). An FDA oncology analysis of antibody-drug conjugates. Regulatory Toxicology and Pharmacology. 71(3). 444–452. 117 indexed citations

13.

Miller, Barry W., Virginia E. Kwitkowski, Haleh Saber, et al.. (2014). U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia. Clinical Cancer Research. 20(15). 3902–3907. 32 indexed citations

14.

Kwitkowski, Virginia E., Chia‐Wen Ko, Mark D. Rothmann, et al.. (2013). U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia. The Oncologist. 19(1). 94–99. 73 indexed citations

15.

Deisseroth, Albert, Edvardas Kaminskas, Joseph A. Grillo, et al.. (2012). U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis. Clinical Cancer Research. 18(12). 3212–3217. 107 indexed citations

16.

Brave, Michael H., Ann T. Farrell, Sarah Pope Miksinski, et al.. (2010). FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous Transplantation. Oncology. 78(3-4). 282–288. 100 indexed citations

17.

Brave, Michael H., Vicki Goodman, Edvardas Kaminskas, et al.. (2008). Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate. Clinical Cancer Research. 14(2). 352–359. 190 indexed citations

18.

Buckley, Lorrene A., Karen Davis‐Bruno, Gregory L. Finch, et al.. (2008). Nonclinical Aspects of Biopharmaceutical Development: Discussion of Case Studies at a PhRMA-FDA Workshop. International Journal of Toxicology. 27(4). 303–312. 12 indexed citations

19.

Kane, Robert C., Ann T. Farrell, Haleh Saber, et al.. (2006). Sorafenib for the Treatment of Advanced Renal Cell Carcinoma. Clinical Cancer Research. 12(24). 7271–7278. 398 indexed citations

20.

Demeler, Borries, Haleh Saber, & Jeffrey C. Hansen. (1997). Identification and interpretation of complexity in sedimentation velocity boundaries. Biophysical Journal. 72(1). 397–407. 134 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact